Learn how AbbVie could help you save on RINVOQ. Call 1-800-2RINVOQ or click to learn more >
If you’re still experiencing PsA symptoms
after a TNF blocker like HUMIRA® or ENBREL® ,
RINVOQ is
and may help
RINVOQ is a JAK inhibitor for adults with active psoriatic arthritis (PsA) in whom TNF blockers did not work well.
If you’re still experiencing PsA symptoms after a TNF blocker like HUMIRA® or ENBREL® ,
RINVOQ is
and may help
RINVOQ is a JAK inhibitor for adults with active psoriatic arthritis (PsA) in whom TNF blockers did not work well.
Proven in clinical studies, RINVOQ can:
Significantly relieve joint pain, swelling, and stiffness for the majority of people in 3 months—for some, PsA symptoms improved in just 2 weeks
Leave skin* clear or almost clear for people with skin plaques
*RINVOQ is not approved to treat plaque psoriasis.
Stop further irreversible joint damage
Significantly reduce PsA fatigue
Not actual size.
Select Important Safety Information
RINVOQ may cause serious side effects, including:
Learn more about these and other serious side effects >
See full Important Safety Information below.
A rheumatologist is your best partner to finding a treatment plan that can help you reach your goals. Partner With a Rheumatologist >
Play an active part in your PsA treatment plan—staying engaged can help you manage PsA symptoms and reach your treatment goals. Partner With a Rheumatologist >
A rheumatologist can evaluate your PsA symptoms and help create a treatment plan that meets your unique needs. Find a Rheumatologist >
HUMIRA® and ENBREL® are examples of TNF blockers. ENBREL® (etanercept) is a registered trademark of Immunex Corporation in the US.
>95% of people with self- or employer-provided insurance plans or Medicare Part D are covered for RINVOQ.†
The RINVOQ Complete Savings Card may help eligible commercially insured patients pay as little as $5 a month‡ for RINVOQ.
Hear how Tim takes on PsA with RINVOQ.
Sign up for the latest tips, tools, and information to help you take PsA head on.
Become a RINVOQ Insider
Share your experience with RINVOQ to help inform and inspire others. To participate, please email us at info@SPEAKnetwork.net or call 877-861-6180.
ENBREL® (etanercept) is a registered trademark of Immunex Corporation in the US.
†National Commercial and Medicare Part D formulary coverage as of June 2023.
‡Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://privacy.abbvie
RINVOQ is a prescription medicine used to treat adults with active psoriatic arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with psoriatic arthritis.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about RINVOQ?
RINVOQ may cause serious side effects, including:
Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects.
What should I do or tell my HCP AFTER starting RINVOQ?
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, increased liver enzyme levels, pneumonia, low number of red blood cells (anemia), and infection of the stomach and intestine (gastroenteritis).
A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ.
Some people taking RINVOQ may see medicine residue (a whole tablet or tablet pieces) in their stool. If this happens, call your healthcare provider.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ?
RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets.
This is the most important information to know about RINVOQ. For more information, talk to your HCP.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
USES
RINVOQ is a prescription medicine used to treat:
It is not known if RINVOQ is safe and effective in children with juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn’s disease.
RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis.
It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.
US-RNQ-220259
Please see the Full Prescribing Information, including the Medication Guide, for RINVOQ.
Legal Notices/Privacy Policy. © 2022 AbbVie. All rights reserved. If you have any questions about AbbVie's RINVOQ.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.
US-RNQR-190268
